Status:

RECRUITING

Natural History of Autosomal Dominant Hearing Loss

Lead Sponsor:

National Institute on Deafness and Other Communication Disorders (NIDCD)

Conditions:

Hearing Loss

Eligibility:

All Genders

3-99 years

Brief Summary

Background: Hereditary hearing loss is one of the most common sensory disabilities affecting newborns. The main options for people with hereditary hearing loss are hearing aids and cochlear implants....

Detailed Description

Hereditary hearing loss is one of the most common sensory disabilities affecting newborns (approximately 1/1000 live births). Currently, the main treatment options for patients with hereditary hearing...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA:
  • Affected persons with autosomal dominant hereditary sensorineural hearing loss, preferably confirmed by prior genetic testing
  • Affected family members of enrolled participants with known autosomal dominant hereditary hearing loss
  • Unaffected Family Members (Healthy Volunteers) of enrolled participant
  • Adults must be able to provide informed consent
  • Minors must have a parent or guardian able to provide informed consent
  • Subjects must be 3-99 years of age
  • EXCLUSION CRITERIA:
  • Persons with sensorineural hearing loss (SNHL) and/or peripheral vestibular dysfunction associated with a non-genetic etiology such as infection, metabolic or immunologic disorders, or exposure to ototoxic agents such as cisplatin, or aminoglycoside antibiotics will not be included in this protocol.
  • Persons with sensorineural hearing loss known to be associated with surgical intervention (e.g. acoustic neuroma removal, failed stapedectomy).
  • Prospective study subjects who are cognitively impaired and lack consent capacity, will not be enrolled. The pre-screening eligibility checklist, which will be used and documented for registration under this protocol, is provided in a separate document.

Exclusion

    Key Trial Info

    Start Date :

    February 9 2021

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    August 21 2029

    Estimated Enrollment :

    1100 Patients enrolled

    Trial Details

    Trial ID

    NCT04501081

    Start Date

    February 9 2021

    End Date

    August 21 2029

    Last Update

    December 24 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    National Institutes of Health Clinical Center

    Bethesda, Maryland, United States, 20892